EPIX | ESSA Pharma Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5800 - 1.6400
52 Week Range	1.4000 - 11.67
Beta	1.91
Implied Volatility	330.23%
IV Rank	59.88%
Day's Volume	245,287
Average Volume	896,388
Shares Outstanding	44,368,958
Market Cap	70,990,333
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-03-13

Valuation
Profitability
Growth
Health
P/E Ratio	-2.50
Forward P/E Ratio	N/A
EPS	-0.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	50
Country	Canada
Website	EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

EPIX's peers: CLSD, DBVT, CYTO, SMMT, ATXI, SPRO, AGLE, JSPR

*Chart delayed

Analyzing fundamentals for EPIX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see EPIX Fundamentals page.

Watching at EPIX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EPIX Technicals page.